Analyst Price Targets — LUCD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 12:46 pm | — | Maxim Group | $2.00 | $0.99 | TheFly | Lucid Diagnostics price target lowered to $2 from $3 at Maxim |
| March 25, 2025 11:25 am | — | BTIG | $2.00 | $1.55 | TheFly | Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG |
| November 13, 2024 5:31 pm | Mike Matson | Needham | $2.50 | $0.79 | StreetInsider | Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| May 14, 2024 8:01 am | Kyle Mikson | Canaccord Genuity | $3.00 | $0.95 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD) |
| April 8, 2024 7:51 am | Mark Massaro | BTIG | $2.50 | $0.93 | StreetInsider | BTIG updates Lucid Diagnostics Inc (LUCD) model post Q4 results |
| November 18, 2022 7:52 am | — | BTIG | $3.50 | $1.91 | Benzinga | BTIG Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.5 |
| November 15, 2022 5:49 am | — | Needham | $3.10 | $2.27 | Benzinga | Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1 |
Latest News for LUCD
Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog and accelerating $8.7M quarterly billable demand. Strong underlying test volume growth, expanding VA access to 9M patients at $1,938/test, and a cash runway into 2027 support LUCD's commercial trajectory. Despite a 1Q26 net loss of $23.6M (impacted by a $9.7M preferred dividend), the…
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing Conference call and webcast to be held…
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health systems.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LUCD.
U.S. House Trading
No House trades found for LUCD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.